ReviewInternational journal of clinical practice2007
Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.
Review in International journal of clinical practice, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 120 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Clinical Trial Comparing the Use of Perioperative Epidural Analgesia to Conventional Intravenous Narcotics and NSAIDS for Patients Undergoing Laparoscopic Colorectal Resection
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
Who cites it
120 citing papers in PubMed, 5 syntheses or guidelines pooled it, 324 citations in OpenAlex.
- Ultrasound-guided fascia iliaca compartment block versus intravenous analgesia in geriatric hip fractures: a systematic review and meta-analysis of randomized trials demonstrating superior pain control.Frontiers in medicine · 2025Pooled it
- Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.The Cochrane database of systematic reviews · 2022Pooled it
- Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.The Cochrane database of systematic reviews · 2018Pooled it
- Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.Pain medicine (Malden, Mass.) · 2017Guideline
- Pharmacological treatment for antipsychotic-related constipation.The Cochrane database of systematic reviews · 2017Pooled it
- Trial
- Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial).Palliative medicine · 2025Trial
- Ultrasound guided retrolaminar block reduces postoperative gastrointestinal system dysfunctions during percutaneous nephrolithotomy: a prospective, randomised, double-blind, clinical study.Scientific reports · 2025Trial
- Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose.Journal of pain research · 2023Trial
- The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation.CPT: pharmacometrics & systems pharmacology · 2017Trial
- Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.European journal of pain (London, England) · 2017Trial
- Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.Advances in therapy · 2016Trial
- Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension.Journal of palliative medicine · 2015Trial
- Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.Clinical drug investigation · 2014Trial
- A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.Palliative medicine · 2012Trial
- Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.Digestive diseases and sciences · 2010Trial
- De-prescribing opioids among Medicaid patients with long-term opioid use.Journal of substance use and addiction treatment · 2025Article
- A short-duration telementoring pain management programme for Medicaid: impact on clinician outcomes.Health education research · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation. Based on clinical experience and a comprehensive MEDLINE literature review, this paper provides the primary care physician with an overview of the prevalence, pathophysiology and burden of OBD. Patients with OBD suffer from a wide range of symptoms including constipation, decreased gastric emptying, abdominal cramping, spasm, bloating, delayed GI transit and the formation of hard dry stools. OBD can have a serious negative impact on quality of life (QoL) and the daily activities that patients feel able to perform. To relieve constipation associated with OBD, patients often use laxatives chronically (associated with risks) or alter/abandon their opioid medication, potentially sacrificing analgesia. Physicians should have greater appreciation of the prevalence, symptoms and burden of OBD. In light of the serious negative impact OBD can have on QoL, physicians should encourage dialogue with patients to facilitate optimal symptomatic management of the condition. There is a pressing need for new therapies that act upon the underlying mechanisms of OBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.